FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2415044568> ?p ?o ?g. }

• W2415044568 abstract "Background Abiraterone acetate (AB) and enzalutamide (EZ) are two agents involved in the inhibition of androgen biosynthesis by blocking androgen receptors, and are used to treat prostate adenocarcinoma (AP) in castration resistant patients before and after progression to docetaxel. Purpose To study the effectiveness and safety of AB and EZ as secondline treatmens after docetaxel in patients with unresectable castration resistant AP resistant to docetaxel. Material and methods Retrospective, observational and analytic study of the treatment of patients with unresectable castration resistant AP that have progressed from a prior treatment with docetaxel in a tertiary hospital. A period of 21 months was considered (January 2014 to September 2015). Patient data were obtained from the oncology patients database (Oncobass v10.1) and the electronic health record database (Mambrino XXI). Demographic data (gender/age) and clinical data (previous and current treatment) were considered for the analysis. Evolution of prostate specific antigen (PSA) was considered to evaluate the rate of response (lack of response, PSA progression at a rate >0.35 ng/ml growth and response maintenance or PSA decline). For the safety analysis we considered values of creatinine (Cr), GGT/ALT/AST and clinical feedback to assess the incidence and severity of adverse events (AEs). Data were collected in Excel 2003 and analysed with matrix SPSS v21, drawing comparisons with χ2 contingency tables by drug dealing and drug response AEs. Results We evaluated 42 patients, mean age 74.02 ± 7.09 years; 20 (47.61%) receiving EZ and 22 (52.39%) receibing AB. The statistical analysis showed no significant difference in efficacy between the lack of EZ (3 (15.00%)) and AB (8 (36.36%)), although there was a trend towards a better response with EZ (p = 0.116). Regarding safety, 30% (6) of treated patients experienced some AEs. For EZ myopathies and tingling were the most  frequent (3 (50%)). AB patients showed no AEs, and there was a clear tendency for AB to be best tolerated than EZ  (p = 0.006). Conclusion EZ and AB treatment appeared to be effective in our cohort of patients with castration resistant AP progression after docetaxel, with a tendency for greater efficacy with EZ, but with a slightly higher profile for side effects compared with AB. It is therefore necessary to assess the risk of particular benefit in patients. No conflict of interest." @default.
• W2415044568 created "2016-06-24" @default.
• W2415044568 creator A5007835370 @default.
• W2415044568 creator A5018121771 @default.
• W2415044568 creator A5052721440 @default.
• W2415044568 creator A5055926380 @default.
• W2415044568 creator A5078784535 @default.
• W2415044568 creator A5082202571 @default.
• W2415044568 creator A5084615803 @default.
• W2415044568 creator A5087166423 @default.
• W2415044568 date "2016-02-14" @default.
• W2415044568 modified "2023-09-27" @default.
• W2415044568 title "CP-207 Analysis of effectiveness and safety of enzalutamide and abiraterone in patients with unresectable prostate adenocarcinoma resistant to castration" @default.
• W2415044568 doi "https://doi.org/10.1136/ejhpharm-2016-000875.207" @default.
• W2415044568 hasPublicationYear "2016" @default.
• W2415044568 type Work @default.
• W2415044568 sameAs 2415044568 @default.
• W2415044568 citedByCount "1" @default.
• W2415044568 countsByYear W24150445682020 @default.
• W2415044568 crossrefType "journal-article" @default.
• W2415044568 hasAuthorship W2415044568A5007835370 @default.
• W2415044568 hasAuthorship W2415044568A5018121771 @default.
• W2415044568 hasAuthorship W2415044568A5052721440 @default.
• W2415044568 hasAuthorship W2415044568A5055926380 @default.
• W2415044568 hasAuthorship W2415044568A5078784535 @default.
• W2415044568 hasAuthorship W2415044568A5082202571 @default.
• W2415044568 hasAuthorship W2415044568A5084615803 @default.
• W2415044568 hasAuthorship W2415044568A5087166423 @default.
• W2415044568 hasConcept C121608353 @default.
• W2415044568 hasConcept C126322002 @default.
• W2415044568 hasConcept C126894567 @default.
• W2415044568 hasConcept C143998085 @default.
• W2415044568 hasConcept C197934379 @default.
• W2415044568 hasConcept C2775832370 @default.
• W2415044568 hasConcept C2776551883 @default.
• W2415044568 hasConcept C2777899217 @default.
• W2415044568 hasConcept C2779256933 @default.
• W2415044568 hasConcept C2780192828 @default.
• W2415044568 hasConcept C2781190966 @default.
• W2415044568 hasConcept C2781406297 @default.
• W2415044568 hasConcept C61367390 @default.
• W2415044568 hasConcept C71315377 @default.
• W2415044568 hasConcept C71924100 @default.
• W2415044568 hasConceptScore W2415044568C121608353 @default.
• W2415044568 hasConceptScore W2415044568C126322002 @default.
• W2415044568 hasConceptScore W2415044568C126894567 @default.
• W2415044568 hasConceptScore W2415044568C143998085 @default.
• W2415044568 hasConceptScore W2415044568C197934379 @default.
• W2415044568 hasConceptScore W2415044568C2775832370 @default.
• W2415044568 hasConceptScore W2415044568C2776551883 @default.
• W2415044568 hasConceptScore W2415044568C2777899217 @default.
• W2415044568 hasConceptScore W2415044568C2779256933 @default.
• W2415044568 hasConceptScore W2415044568C2780192828 @default.
• W2415044568 hasConceptScore W2415044568C2781190966 @default.
• W2415044568 hasConceptScore W2415044568C2781406297 @default.
• W2415044568 hasConceptScore W2415044568C61367390 @default.
• W2415044568 hasConceptScore W2415044568C71315377 @default.
• W2415044568 hasConceptScore W2415044568C71924100 @default.
• W2415044568 hasLocation W24150445681 @default.
• W2415044568 hasOpenAccess W2415044568 @default.
• W2415044568 hasPrimaryLocation W24150445681 @default.
• W2415044568 isParatext "false" @default.
• W2415044568 isRetracted "false" @default.
• W2415044568 magId "2415044568" @default.
• W2415044568 workType "article" @default.